MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · Real-Time Price · USD

55.65

+0.81 (1.48%)

At close: Aug 13, 2025, 4:00 PM

55.65

0.00 (0.00%)

Pre-market: Aug 14, 2025, 8:31 AM EDT

MLTX Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	38.56	30.32	22.32	23.01	21.66
Research & Development	162.32	112.77	31.8	42.05	12.64
Operating Expenses	200.88	143.09	54.12	65.06	34.29
Operating Income	-200.88	-143.09	-54.12	-65.06	-34.29
Currency Exchange Gain (Loss)	0.48	0.04	0.15	0.33	-0.07
Other Non Operating Income (Expenses)	23.71	22.09	9.99	0.27	-0
EBT Excluding Unusual Items	-178.74	-120.96	-43.98	-64.47	-34.37
Other Unusual Items	-	-	-	-	-30
Pretax Income	-178.74	-120.96	-43.98	-64.47	-64.37
Income Tax Expense	0.38	0.28	0.09	0.04	0.01
Earnings From Continuing Operations	-179.12	-121.24	-44.08	-64.51	-64.37
Minority Interest in Earnings	2.96	2.31	8.07	14.53	-
Net Income	-176.16	-118.94	-36.01	-49.97	-64.37
Net Income to Common	-176.16	-118.94	-36.01	-49.97	-64.37
Shares Outstanding (Basic)	63	63	49	29	8
Shares Outstanding (Diluted)	63	63	49	29	8
Shares Change (YoY)	5.56%	27.99%	67.30%	274.47%	-
EPS (Basic)	-2.79	-1.89	-0.73	-1.70	-8.21
EPS (Diluted)	-2.79	-1.89	-0.73	-1.70	-8.21
Free Cash Flow	-166.76	-117.11	-43.06	-55.91	-42.27
Free Cash Flow Per Share	-2.64	-1.86	-0.88	-1.90	-5.39
EBITDA	-199.04	-141.71	-53.75	-64.9	-34.29
D&A For EBITDA	1.83	1.38	0.37	0.16	0.01
EBIT	-200.88	-143.09	-54.12	-65.06	-34.29

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q